Related Experiment Video

Updated: Jun 7, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

6.9K

IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma

Shriya Deshmukh1, Ciara Kelly2, Gabriel Tinoco3

  • 1Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Targeted Oncology
|November 15, 2024
PubMed

Insights

Novel isocitrate dehydrogenase (IDH) inhibitors show promise for treating chondrosarcoma, a rare bone cancer. This review explores IDH-mutated cancer pathogenesis and potential combination therapies for advanced disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chondrosarcomas are rare bone cancers with limited treatment options for advanced or metastatic disease.
  • A high prevalence (50-80%) of isocitrate dehydrogenase (IDH) gene mutations is observed in chondrosarcomas.
  • Current systemic therapies lack substantial effectiveness, highlighting an unmet clinical need.

Purpose of the Study:

  • To review the role of IDH mutations in chondrosarcoma pathogenesis.
  • To explore recent advancements in IDH inhibitor development for chondrosarcoma treatment.
  • To propose future clinical trial strategies involving IDH inhibitors.

Main Methods:

  • Literature review of IDH-mediated pathogenesis in chondrosarcoma.
  • Analysis of current pharmacological advances and novel IDH inhibitors.
  • Exploration of potential therapeutic strategies and combination treatments.

Main Results:

  • IDH mutations are a key driver in a majority of chondrosarcomas.
  • Novel IDH inhibitors demonstrate potential therapeutic value.
  • Combination therapies may enhance treatment efficacy.

Conclusions:

  • IDH inhibitors represent a promising targeted therapy for chondrosarcoma.
  • Further research and clinical trials are essential to establish the efficacy of IDH inhibitors, potentially in combination regimens.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

246

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K